GLP‑1 boom extends beyond pharma

Glucagon-like peptide-1 drugs, the appetite-slowing medicines sold as Wegovy, Zepbound and Ozempic, are now reshaping businesses far beyond drugmakers. (theconversation.com) Business Insider reported on April 11 that users are spending on trainers, supplements, cosmetic procedures and replacement wardrobes as rapid weight loss changes bodies and habits. One Ozempic user, Kelly Freeman, said he pays about $112 a month for the drug itself and roughly $700 to $1,000 a month on related costs. (businessinsider.com) The customer base is large enough to move markets. A Kaiser Family Foundation poll published November 14, 2025 found 12% of U.S. adults said they were currently taking a glucagon-like peptide-1 drug for weight loss, diabetes or another condition. (kff.org) These medicines work by mimicking a gut hormone that helps the pancreas release insulin and slows how quickly food leaves the stomach, which makes people feel full sooner and often eat less. The result is not only lower calorie intake, but a shift in what people buy, including more protein-focused foods and products aimed at preserving muscle. (theconversation.com, pwc.com) Price and convenience are pushing the trend into a new phase. The Atlantic reported on April 12 that the United States is moving toward a “shot to lose weight, then a pill to keep it off” model as oral glucagon-like peptide-1 options reach the market. (theatlantic.com) That expansion is arriving with a maintenance problem doctors have warned about for years. The Conversation reported in February that many patients regain weight after stopping glucagon-like peptide-1 drugs because the body tends to defend its prior weight, a response physicians call metabolic adaptation. (theconversation.com) That helps explain why gyms, strength coaches and protein supplement sellers are drawing interest from users trying to limit muscle loss during treatment and hold onto results afterward. Business Insider identified fitness, supplements, fashion and plastic surgery as four sectors already seeing gains from the boom. (businessinsider.com) Consulting firm PwC has been warning consumer companies that glucagon-like peptide-1 adoption can change how much people eat, how often they eat and what they expect from food, beverage, retail and travel brands. Its survey said those individual behavior changes can add up across multiple industries at once. (pwc.com) The next test is whether those spillover businesses can keep customers after the first wave of weight loss. The drugs may start in a prescription pad, but the longer fight is moving into closets, grocery carts and gym memberships. (businessinsider.com, theconversation.com)